Dolutegravir
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 15/2022/ÚVN | 05. 01. 2022 | GlaxoSmithKline, s.r.o. | 21 880 066,56 | 19 890 969,60 | 21 880 066,56 | 19 890 969,60 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| Písemná zpráva Dolutegravir signed 17012022.pdf | Písemná zpráva zadavatele | 17. 01. 2022 15:36 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| GlaxoSmithKline, s.r.o. | Praha |
Price Actually Paid in Each Year of Performance
| 15/2022/ÚVN | 2023 | 5 189 843,50 | 4 718 040,96 |
| 15/2022/ÚVN | 2022 | 4 002 450,00 | 3 638 592,00 |